Cargando…
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413020/ https://www.ncbi.nlm.nih.gov/pubmed/37577327 http://dx.doi.org/10.21037/tlcr-23-273 |
| _version_ | 1785087043530915840 |
|---|---|
| author | Patel, Shruti R. Neal, Joel W. |
| author_facet | Patel, Shruti R. Neal, Joel W. |
| author_sort | Patel, Shruti R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10413020 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104130202023-08-11 Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Patel, Shruti R. Neal, Joel W. Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2023-06-12 2023-07-31 /pmc/articles/PMC10413020/ /pubmed/37577327 http://dx.doi.org/10.21037/tlcr-23-273 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Patel, Shruti R. Neal, Joel W. Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title | Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title_full | Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title_fullStr | Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title_full_unstemmed | Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title_short | Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? |
| title_sort | adjuvant osimertinib for resected egfr-mutated non-small cell lung cancer: a game-changer? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413020/ https://www.ncbi.nlm.nih.gov/pubmed/37577327 http://dx.doi.org/10.21037/tlcr-23-273 |
| work_keys_str_mv | AT patelshrutir adjuvantosimertinibforresectedegfrmutatednonsmallcelllungcanceragamechanger AT nealjoelw adjuvantosimertinibforresectedegfrmutatednonsmallcelllungcanceragamechanger |